Does the Vaccination against Tick-Borne Encephalitis Offer Good Value for Money for Incidence Rates below the WHO Threshold for Endemicity? A Case Study for Germany
Our results support a recommendation for TBE vaccination even in settings with low numbers of reported cases, especially for older patients. Furthermore, this analysis identified major research gaps regarding the costs, utilities, and clinical progression of TBE.
Authors
- Claudius Malerczyk
- Malina Müller (ORCID: https://orcid.org/0009-0004-4846-2746)
- Kate Halsby
- Jennifer C. Moïsi (ORCID: https://orcid.org/0000-0002-7137-5630)
- Andreas Pilz (ORCID: https://orcid.org/0000-0002-6394-3845)
- Holly Yu (ORCID: https://orcid.org/0000-0001-8625-4201)
- Hannah Lintener
- Harish Madhava
- Katharina Schley (ORCID: https://orcid.org/0000-0002-0975-4154)
- V. Henkel
Institutions
- Pfizer (United States) (US)
- Pfizer (United Kingdom) (GB)
- Heidelberg University (DE)
- University Hospital Heidelberg (DE)
- Pfizer (Germany) (DE)
- Pfizer (France) (FR)
- Pfizer (Austria) (AT)
Publication Details
- Journal
- Vaccines
- Published
- 2024-10-12
- DOI
- https://doi.org/10.3390/vaccines12101165
- Citations
- 8
- Primary Topic
- Vector-borne infectious diseases
- Type
- article
- Field-Weighted Citation Impact
- 4.12
Funders
- Pfizer